Sign In
Buy SAGE
$8.68
+0 (+0%)
At Close: Oct 30, 2025
Stockholder Notice: Robbins LLP Informs Stockholders of the Class Action Filed Against Sage Therapeutics, Inc.
03:37pm, Thursday, 29'th Aug 2024
SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Sage Ther
SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sage Therapeutics, Inc. (NASDAQ: SAGE) securities between April 12, 2021 and Jul
ATLANTA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Sage Therapeutics, Inc. (“Sage Therapeutics” or “the Company”) (NASDAQ: SAGE). The lawsuit
Sage Therapeutics Inc. Is Being Inquired Into For Securities Impropriety And The Schall Law Firm Wants Impacted Investors To Reach Out
11:00am, Thursday, 29'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeuti
Pomerantz Law Firm Announces the Filing of a Class Action Against Sage Therapeutics, Inc. and Certain Officers – SAGE
10:00pm, Wednesday, 28'th Aug 2024
NEW YORK, NY / ACCESSWIRE / August 28, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ:SAGE) and certain off
LOS ANGELES, CA / ACCESSWIRE / August 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeuti
The Schall Law Firm Is Looking Into Possible Securities Infractions By Sage Therapeutics Inc And Investors Are Urged To Participate
11:00am, Tuesday, 27'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeuti
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE)
LOS ANGELES, CA / ACCESSWIRE / August 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeuti
The Schall Law Firm Is Inquiring Into Sage Therapeutics Inc For Securities Fraud And Stockholders Are Invited To Play A Part
11:00am, Saturday, 24'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeuti
Sage Therapeutics Inc Is Being Looked Into By The Schall Law Firm For Securities Law Violations And Investors Are Asked To Join
11:00am, Friday, 23'rd Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeuti
LOS ANGELES, CA / ACCESSWIRE / August 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeuti
LOS ANGELES, CA / ACCESSWIRE / August 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeuti
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sage Therapeutics, Inc. - SAGE
12:45pm, Monday, 19'th Aug 2024
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ:SAGE). Such investors are advise
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sage Therapeutics, Inc. - SAGE
10:10pm, Saturday, 17'th Aug 2024
NEW YORK , Aug. 17, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE). Such investors are ad
